Axsome Therapeutics (AXSM) Cash from Operations Growth (1y) (2016 - 2026)
Powered by 
Analysis
Axsome Therapeutics (AXSM) Cash from Operations Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 42.76% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.58% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 151.70% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 100.14% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 56.79% |
| 10 | Axsome Therapeutics | 10.75 Bn | 10.43 Bn | 204.81 Mn | -1.63% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.63% |
| Mar 31, 2026 | 52.28% |
| Dec 31, 2025 | 28.81% |
| Sep 30, 2025 | 105.61% |
| Jun 30, 2025 | -7.68% |
| Mar 31, 2025 | 18.88% |
| Dec 31, 2024 | 13.70% |
| Sep 30, 2024 | 65.21% |
| Jun 30, 2024 | 45.60% |
| Mar 31, 2024 | -818.52% |
| Dec 31, 2023 | -10.15% |
| Sep 30, 2023 | -135.29% |
| Jun 30, 2023 | -65.04% |
| Mar 31, 2023 | 82.17% |
| Dec 31, 2022 | 4.43% |
| Sep 30, 2022 | 15.01% |
| Jun 30, 2022 | -32.07% |
| Mar 31, 2022 | -19.98% |
| Dec 31, 2021 | -40.32% |
| Sep 30, 2021 | -70.17% |